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Abstract
Introduction: Paraneoplastic necrotizing myopathy is a rare disorder, described as a proximal,
symmetrical, and rapidly progressing myopathy that is manifested as a paraneoplastic syndrome.
Diagnosis is established via histological examination of the muscle biopsy.
Case presentation: We present the case of a 53-year-old woman, born in Guinea-Bissau, with a
history of locally advanced breast cancer, diagnosed ten months previously. The patient had
experienced a progressively proximal muscle weakness of the lower extremities, which led to a
total inability to walk. Upon neurological examination, the patient showed muscle weakness and
atrophy in both proximal lower extremities without myalgia. Muscle strength was graded according
to the Medical Research Council Scale as 2 out of 5 in the bilateral iliopsoas muscle, and 4 out of
5 in the bilateral quadriceps femoris. The deep-tendon reflexes were hypoactive. The laboratory
examination showed increased values of serum creatinine kinase and myoglobin. An
electromyogram showed an incomplete interference pattern during voluntary contraction in the
iliopsoas and quadriceps femoris. The motor nerve conduction was 44.1 m/s and 44.3 m/s in the
right and left tibial nerves, respectively, and 46.5 m/s and 46.1 m/s in the right and left peroneal
nerves, respectively. The sensory motor nerve conductions and the compound motor action
potential amplitudes were normal. These findings, despite not being specific, suggested a myopathy.
Consequently, a muscle biopsy was performed. A biopsy specimen showed myopathic changes that
were characteristic of a necrotizing myopathy.
Conclusion:  Treatment for this syndrome consists of controlling the tumor, and providing
corticoid therapy. This led to the partial remission of the neurological manifestations.
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Introduction
Neurologic paraneoplastic syndromes are characterized
by neurological dysfunctions occuring in patients with
cancer that are not attributed to a direct invasion of the
central nervous system or to metastatic lesions. Neuro-
logic paraneoplastic syndromes occur in less than 1% of
patients with cancer [1] and usually precede the diagnosis
of the cancer. The etiopathogenesis of these entities is
unknown, and they are classified according to their ana-
tomic location [2,3].
Paraneoplastic necrotizing myopathy is a rare entity. In
the published literature, Levin et al. were only able to
identify four patients. Necrotizing myopathy has been
associated with multiple neoplasms, the most frequent
being gastrointestinal tract adenocarcinoma, prostate ade-
nocarcinoma, bladder cancer, and non-small cell lung
cancer [4,5].
This entity is characterized by a symmetric and proximal
myopathy accompanied by an increase of the serum levels
of the muscle enzymes and by electromyography (EMG)
findings suggestive of a nonspecific myopathy [2,6]. The
diagnosis of paraneoplastic necrotizing myopathy is his-
tological [5]. The muscle biopsy shows evidence of a mas-
sive necrosis of the muscle fibers with almost complete
absence of inflammatory infiltrate. This latter feature
allows necrotizing myopathy to be distinguished from
other myopathies also associated with paraneoplastic
neurologic syndromes, such as dermatomyositis and pol-
ymyositis [7,8].
We present the case of a female patient with a locally
advanced breast carcinoma, and with a final diagnosis of
necrotizing myopathy. The diagnostic steps and subse-
quent therapeutic attitudes are discussed.
Case presentation
A 53-year-old woman, born in Guinea-Bissau, was admit-
ted in São Francisco Xavier Hospital with a progressively
proximal muscle weakness of the lower extremities that
had led to a total inability to walk. The patient had a his-
tory of a locally advanced breast cancer diagnosed ten
months earlier. The tumour was 4 × 5 cm and located in
her right breast with ulceration to the skin and with axil-
lary adenopathies. Biopsies revealed an invasive ductal
carcinoma with extensive tumor necrosis. Immunocyto-
chemical staining was negative for hormonal receptors
(estrogens and progesterone) and positive for c-erbB2
(Score 3+). The staging of the neoplastic disease, con-
ducted through axillary echography, computerized tom-
ography (CT) of the thorax, abdomen and pelvis, and
bone scintigraphy, revealed a IIIC stage according to the
Tumor-Node-Metastases (TNM) classification. Primary
chemotherapy was performed with epirubicin and
docetaxel, associated with radiotherapy of the primary
lesion (3400 rads total). Given the absence of a reduction
of the tumoral mass, the chemotherapy scheme was mod-
ified to cyclophosphamide, methotrexate and 5-fluorour-
acil (CMF).
Ten months later, the patient presented with signs of
lower back pain with radiation towards both lower
extremities accompanied by a decrease in muscle strength.
Upon neurological examination, the patient presented
muscle weakness and atrophy of both proximal lower
extremities without myalgia. Muscle strength was graded
according to the Medical Research Council Scale (MRC) as
2 out of 5 in the bilateral iliopsoas muscle, and 4 out of 5
in the bilateral quadriceps femoris. The deep-tendon
reflexes were hypoactive. No other findings were encoun-
tered in the neurological examination.
There was no history of diabetes mellitus, alcoholism,
toxin exposure, blood transfusion, nutritional deficiency,
or any medication besides the chemotherapy above men-
tioned.
The following complementary examinations were per-
formed: lumbar puncture, CT and magnetic resonance
scans of the lumbosacral column, and tumor markers. All
the results were normal. The laboratorial evaluation at
this time indicated only a small elevation of creatinine
kinase (CK) values (300 IU/l). In view of these results, the
provisional diagnosis of secondary neuropathy due to
docetaxel was considered, with the patient maintaining
the CMF cycles and starting gabapentin. At this stage, and
given the reduction of the tumor mass and partial recovery
of the muscular strength (according to the MRC Scale as 4
out of 5 in the bilateral iliopsoas muscle, and 4 out of 5 in
the bilateral quadriceps femoris), the patient was submit-
ted to a modified radical mastectomy and was discharged
from the hospital.
Three months later, the patient was readmitted due to new
neurological deterioration. Muscle strength was graded
according to the MRC Scale as 2 out of 5 in the bilateral
iliopsoas muscle and 2 out of 5 in both quadriceps femo-
ris, although it was nearly normal in other muscles. The
muscles innervated by cranial nerves were spared. The
deep-tendon reflexes were hypoactive.
The laboratorial re-evaluation showed a marked increase
in serum CK values (2400 IU/l), serum myoglobin (780
IU/l), and moderate elevation of serum aminotransferases
(alanine aminotransferase: 300 IU/l). Viral examination
(serological markers for hepatitis B, C, HIV and human T-
lymphotropic virus) was negative.Journal of Medical Case Reports 2009, 3:95 http://www.jmedicalcasereports.com/content/3/1/95
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An EMG showed an incomplete interference pattern with
poor activation during voluntary contraction in the iliop-
soas and quadriceps femoris. The motor nerve conduction
was 44.1 m/s and 44.3 m/s in the right and left tibial
nerves, respectively, and 46.5 m/s and 46.1 m/s in the
right and left peroneal nerves, respectively. The sensory
motor nerve conductions and the compound motor
action potential amplitudes were normal.
One week later, a biopsy specimen of the left quadriceps
femoris presented a muscle necrosis pattern, increased
centrally placed nuclei consisting of 3% of total fibers,
and substantial numbers of scattered necrotic and regen-
erating fibers without inflammatory cells. A diffuse
replacement of the muscle tissue by adipose and conjunc-
tive tissues was also encountered (Figure 1, Figure 2, Fig-
ure 3 and Figure 4).
The following screening tests for inflammatory myopa-
thies were conducted: antinuclear antibodies; anti-
smooth muscle antibodies (ab); anti-ribonucleoprotein
ab; anti-proliferating cell nuclear antigen ab; anti Mi2 ab;
anti Jo1 ab; anti-SS A and anti SS B ab; and anti-scl 70 ab.
Complement levels were normal.
A new staging of the neoplastic disease was also con-
ducted, and revealed an absence of metastases.
The diagnosis of necrotizing myopathy was attributed,
and corticotherapy was initiated (prednisolone 1.5 mg/
kg/day), while still maintaining the chemotherapy already
established. A full recovery of muscle strength was
observed.
Four months later, a new decrease of muscle strength was
observed, and the patient noticed difficulties standing up
and raising her arms above shoulder height. Muscle
strength was graded according to MRC as 3 out of 5 in the
bilateral deltoids, biceps brachii and triceps brachii, and 2
out of 5 in the bilateral iliopsoas muscle and in both
quadriceps femoris, but still maintaining distal strength.
The muscles innervated by cranial nerves were still spared.
The EMG and muscle biopsy of the left biceps brachii
muscle were repeated one week later. The EMG showed
the same incomplete interference pattern during volun-
tary contraction in bilateral deltoids, biceps brachii, tri-
Muscle biopsy of the quadriceps femoris (hematoxilin-eosin  stain, ×100) Figure 1
Muscle biopsy of the quadriceps femoris (hematoxi-
lin-eosin stain, ×100). Necrotic vacuolated and regenerat-
ing muscle fibres are present. Endomysial connective tissue is 
increased. Inflammatory infiltrate is absent.
Detail of muscle biopsy of the quadriceps femoris (hematoxi- lin-eosin stain, ×350), showing myopathic changes composed  of scattered necrotic (star) and regenerating (arrow) fibers Figure 2
Detail of muscle biopsy of the quadriceps femoris 
(hematoxilin-eosin stain, ×350), showing myopathic 
changes composed of scattered necrotic (star) and 
regenerating (arrow) fibers.
Muscle biopsy of the quadriceps femoris (alkaline phosphates  stain, ×100) Figure 3
Muscle biopsy of the quadriceps femoris (alkaline 
phosphates stain, ×100). This staining emphasizes the 
regenerating fibers and perimysial connective tissue.Journal of Medical Case Reports 2009, 3:95 http://www.jmedicalcasereports.com/content/3/1/95
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ceps brachii, iliopsoas and quadriceps femoris. The motor
nerve conduction velocity was: 44.4 and 45 m/s in right
and left median nerves, 49.5 and 48.7 m/s in right and left
ulnar nerves, and 39.6 and 40.3 m/s in right and left per-
oneal nerves, respectively. The sensory motor nerve con-
ductions and the compound motor action potential
amplitudes were still normal. The biopsy specimen
showed the same myopathic changes encountered in the
first muscle biopsy.
At the same time, the re-staging of the neoplastic disease
showed evidence of bone metastases in the sternum,
which were confirmed by bone tomography and scintigra-
phy. Reinstitution of chemotherapy was established with
epirubicin and docetaxel, and corticotherapy was intensi-
fied (3 mg/kg/day).
Three weeks later a progressive improvement of the mus-
cle strength was observed with a partial recovery of the
ability to walk. Muscle strength was graded according to
MRC as 4 out of 5 in bilateral deltoids, biceps brachii, and
triceps brachii and 3 out of 5 in the bilateral iliopsoas
muscle and in both quadriceps femoris. The serum muscle
enzymes returned to normal values.
The patient died one year later with pulmonary and
hepatic failure due to metastasization of the underlying
cancer.
Discussion
In this report we describe a paraneoplastic necrotizing
myopathy in a patient with breast cancer. The patient pre-
sented a progressive, proximal and symmetric myopathy
with serum increases of the muscle enzymes. These ele-
ments should point to this entity. Despite these findings,
diagnosis is only established through muscle biopsy. The
histological examination of the biopsy revealed a massive
necrosis of muscle fibers without inflammatory cell infil-
trates. This latter feature allows the pathologist to distin-
guish necrotizing myopathy from other myopathies that
are frequently associated to paraneoplastic syndromes,
such as dermatomyositis and polymyositis.
In our patient, however, the diagnostic strength of the
muscle biopsy had some limitations due to lack of immu-
nohistochemical stainings for inflammatory cells and
complement. Nevertheless, the results observed (a mas-
sive necrosis of muscle fibers without inflammatory T-
cells infiltrates) in the hematoxylin-eosin and in acid
phosphatase stainings support the diagnosis of a parane-
oplastic necrotizing myopathy.
Paraneoplastic necrotizing myopathy associated with
breast cancer is a rare entity: only three cases have been
described in literature [5]. The absence of inflammation
suggests that humoral immunologic mechanisms may be
involved [5].
The rapid and symmetrical progression of this neurologi-
cal condition suggests a radicular lumbosacral syndrome
due to meningeal carcinomatosis or medullar compres-
sion. Because they occur more often among cancer
patients, these diagnoses could delay the diagnosis of
necrotizing myopathy. These hypotheses were therefore
excluded.
The initial hypothesis of secondary neuropathy due to
toxins or drugs was also excluded since there was no his-
tory of toxic exposure and no recovery was observed when
chemotherapy with docetaxel was modified. Despite these
drugs usually causing sensitive neuropathy, severe senso-
rimotor neuropathy has been described in some patients
[2,9]. For this patient, however, the clinical picture (prox-
imal weakness without sensory symptoms) was more con-
sistent with a diagnosis of myopathy. This diagnosis was
also supported by the findings in the EMG.
The aggressiveness of the underlying neoplastic disease,
demonstrated by a difficult response to antineoplastic
therapy, could lead to difficulty in improving neurological
symptoms. Because paraneoplastic syndromes differ
widely from one patient to another, prognosis may vary
greatly according to the clinical and immunological fea-
tures. Two groups of disorders have been considered: one
group includes disorders mediated by antibodies against
cell surface neuronal antigens - these syndromes often
respond to treatment and have a favorable outcome, and
another group includes disorders mediated by T-cell
mechanisms, which respond poorly to treatment, and
have a less favourable outcome [10].
Muscle biopsy of the quadriceps femoris (alkaline phosphates  stain, ×100) showing myopathic changes composed of scat- tered necrotic (arrow) fibers Figure 4
Muscle biopsy of the quadriceps femoris (alkaline 
phosphates stain, ×100) showing myopathic changes 
composed of scattered necrotic (arrow) fibers.Publish with BioMed Central    and   every 
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There could, therefore, be a parallel between the severity
of the underlying neoplastic disease and the clinical sever-
ity of the paraneoplastic syndrome. This patient showed
improvements, with a partial recovery of the ability to
walk, when the immunosuppressive therapy was intensi-
fied.
Conclusion
Paraneoplastic syndromes are rare neurological complica-
tions in patients with cancer [11]. Necrotizing myopathy
can induce a worse prognosis and a greater disability for
the patient. It is important, therefore, to establish an early
diagnosis of this entity because prompt diagnosis of the
tumor and immunosuppressive therapy may positively
impact the clinical outcome and improve the quality of
life of patients with paraneoplastic syndromes.
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